Kezar Life Sciences (NASDAQ:KZR) Rating Reiterated by HC Wainwright

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Monday, Benzinga reports.

Kezar Life Sciences Price Performance

Shares of NASDAQ KZR opened at $0.85 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.58 and a quick ratio of 9.58. The firm has a market capitalization of $61.71 million, a PE ratio of -0.61 and a beta of 0.21. Kezar Life Sciences has a 1-year low of $0.52 and a 1-year high of $1.14. The business’s fifty day moving average price is $0.63 and its two-hundred day moving average price is $0.69.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, research analysts expect that Kezar Life Sciences will post -1.2 EPS for the current year.

Institutional Trading of Kezar Life Sciences

Hedge funds have recently added to or reduced their stakes in the business. Ikarian Capital LLC lifted its position in Kezar Life Sciences by 1.8% in the first quarter. Ikarian Capital LLC now owns 868,992 shares of the company’s stock worth $783,000 after purchasing an additional 15,601 shares during the period. Fidelis Capital Partners LLC bought a new position in Kezar Life Sciences during the first quarter valued at about $25,000. Vanguard Group Inc. grew its holdings in Kezar Life Sciences by 1.0% during the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after acquiring an additional 30,740 shares during the period. Mackenzie Financial Corp acquired a new position in Kezar Life Sciences during the second quarter worth about $35,000. Finally, Acadian Asset Management LLC raised its position in Kezar Life Sciences by 3.6% in the second quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock worth $1,112,000 after acquiring an additional 64,356 shares in the last quarter. Institutional investors own 67.90% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.